- Source : Press Release
- Date : 2019-06-27
- Companies : Bactiguard AB
New Swedish Study Shows That Long-Term Use of Bactiguard Coated Foley Catheters Reduce Infections
A recently published clinical case study conducted at the Central Hospital in Karlstad, Sweden, shows that long-term use of Bactiguard coated Foley (BIP Foley) catheters reduces catheter associated urinary tract infections (CAUTIs) and greatly improves the patient’s quality of life.
”Permanent use of Foley catheters is often associated with frequently recurring urinary tract infections, which have a significant negative impact on the patients’ wellbeing and quality of life. This study confirms that using BIP Foley catheters reduces the risk of infections and leads to pronounced health benefits for long-term users, who may be chronically dependent on catheterization,” says Jonas Östregård, SVP Sales & Marketing at Bactiguard.
The objective of the study was to investigate the effect of using BIP Foleys on a patient, permanently catheterized with suprapubic catheter. Despite several infection preventive approaches and attempts, the patient suffered from frequently recurring catheter related urinary tract infections (CAUTIs) for many years. These infections required antibiotic treatments and healthcare nearly every month. One month after switching to the BIP Foley catheter from Bactiguard, the CAUTI symptoms disappeared and the patient remained free of symptomatic CAUTIs and subsequent antibiotic treatment for the entire 2.5-year study period.
In addition, the patient was more satisfied with the comfort during insertion, use and removal of the BIP Foley catheters compared to the catheters previously used.
The study is published in Therapeutic Advances in Urology, read the full article: https://journals.sagepub.com/doi/pdf/10.1177/1756287219854915
Bactiguard's Foley catheters have been procured for the following regions/county councils in Sweden: Stockholm, Skåne, Östergötland, Värmland, Halland, Kronoberg, Kalmar, Blekinge and Västra Götaland. These regions together account for about 70% of Sweden's population.
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives at www.bactiguard.com